TN2011000263A1 - Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease - Google Patents

Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease

Info

Publication number: TN2011000263A1
Authority: TN; Tunisia
Prior art keywords: treatment; pyridyloxyindoles; vegf; inhibitors; disease
Prior art date: 2008-12-09

Application number

TN2011000263A

Other languages

English (en)

Inventor

Jason Matthew Elliott

Nan Ji

Donglei Liu

Fupeng Ma

Nello Mainolfi

Erik Meredith

Karl Miranda

James J Powers

Chang Rao

Iii Gerald David Artman

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-09

Filing date

2011-05-23

Publication date

2012-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42034535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-23 Application filed by Novartis Ag filed Critical Novartis Ag

2012-12-17 Publication of TN2011000263A1 publication Critical patent/TN2011000263A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

TN2011000263A 2008-12-09 2011-05-23 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease TN2011000263A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20124308P	2008-12-09	2008-12-09
US23334109P	2009-08-12	2009-08-12
PCT/EP2009/066540 WO2010066684A2 (fr)	2008-12-09	2009-12-07	Inhibiteurs pyridyloxyindoles de vegf-r2 et utilisation thérapeutique de ceux-ci

Publications (1)

Publication Number	Publication Date
TN2011000263A1 true TN2011000263A1 (en)	2012-12-17

Family

ID=42034535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000263A TN2011000263A1 (en)	2008-12-09	2011-05-23	Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease

Country Status (39)

Country	Link
US (6)	US8242125B2 (fr)
EP (1)	EP2376478B1 (fr)
JP (1)	JP5580330B2 (fr)
KR (1)	KR101345956B1 (fr)
CN (2)	CN103193773B (fr)
AR (1)	AR074499A1 (fr)
AU (1)	AU2009326110B9 (fr)
BR (1)	BRPI0922552A2 (fr)
CA (1)	CA2745922C (fr)
CL (1)	CL2011001378A1 (fr)
CO (1)	CO6382119A2 (fr)
CR (1)	CR20110270A (fr)
CU (1)	CU24097B1 (fr)
CY (1)	CY1119091T1 (fr)
DK (1)	DK2376478T3 (fr)
EA (1)	EA019681B1 (fr)
EC (1)	ECSP11011113A (fr)
ES (1)	ES2633959T3 (fr)
HN (1)	HN2011001593A (fr)
HR (1)	HRP20171075T1 (fr)
HU (1)	HUE035292T2 (fr)
IL (1)	IL213068A (fr)
JO (1)	JO3265B1 (fr)
LT (1)	LT2376478T (fr)
MX (1)	MX2011006093A (fr)
MY (1)	MY155649A (fr)
NZ (2)	NZ593030A (fr)
PE (1)	PE20110835A1 (fr)
PL (1)	PL2376478T3 (fr)
PT (1)	PT2376478T (fr)
RS (1)	RS56076B1 (fr)
SG (1)	SG171784A1 (fr)
SI (1)	SI2376478T1 (fr)
SV (1)	SV2011003939A (fr)
TN (1)	TN2011000263A1 (fr)
TW (1)	TWI429640B (fr)
UY (1)	UY32302A (fr)
WO (1)	WO2010066684A2 (fr)
ZA (1)	ZA201103759B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2350075E (pt)	2008-09-22	2014-06-09	Array Biopharma Inc	Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
AR077468A1 (es)	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US20130197016A1 (en) *	2010-10-27	2013-08-01	Mitchell Brigell	Dosing regimes for the treatment of ocular vascular disease
CN102786469B (zh) *	2011-05-18	2016-09-14	中国医学科学院药物研究所	邻吡啶酰肼衍生物及其制法和药物组合物与用途
US9056874B2 (en)	2012-05-04	2015-06-16	Novartis Ag	Complement pathway modulators and uses thereof
AP2014008040A0 (en) *	2012-05-04	2014-10-31	Novartis Ag	Complement pathway modulators and uses thereof
KR101315227B1 (ko) *	2012-05-30	2013-10-07	엘지디스플레이 주식회사	터치스크린 일체형 표시장치 및 그 구동 방법
ES2648962T3 (es) *	2012-06-28	2018-01-09	Novartis Ag	Derivados de pirrolidina y su uso como moduladores de la vía del complemento
JP6155332B2 (ja) *	2012-06-28	2017-06-28	ノバルティスアーゲー	ピロリジン誘導体、および補体経路調節因子としてのその使用
WO2014002051A2 (fr) *	2012-06-28	2014-01-03	Novartis Ag	Modulateurs de la voie du complément et leurs utilisations
US9388199B2 (en) *	2012-06-28	2016-07-12	Novartis Ag	Pyrrolidine derivatives and their use as complement pathway modulators
CN104640855B (zh) *	2012-06-28	2017-08-29	诺华股份有限公司	补体途经调节剂及其用途
WO2014002057A1 (fr) *	2012-06-28	2014-01-03	Novartis Ag	Dérivés de pyrrolidine et leur utilisation en tant que modulateurs des voies du complément
CN104684910B (zh) *	2012-07-12	2016-10-12	诺华股份有限公司	补体途经调节剂及其用途
CN103570616B (zh) *	2012-07-18	2017-10-20	中国医学科学院药物研究所	N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途
WO2014143638A1 (fr)	2013-03-14	2014-09-18	Novartis Ag	Dérivés de 2-(1h-indol-4-ylméthyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile comme inhibiteurs du facteur b du complément utiles pour le traitement de maladies ophtalmiques
WO2014154173A1 (fr) *	2013-03-28	2014-10-02	广州康睿生物医药科技有限公司	Composé anti-angiogénique
US20150018376A1 (en) *	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
US10174006B2 (en) *	2013-06-06	2019-01-08	Novartis Ag	Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
JO3425B1 (ar)	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
JP6522502B2 (ja)	2013-07-29	2019-05-29	協和発酵キリン株式会社	Ｗｎｔシグナル阻害剤
WO2015066241A1 (fr)	2013-10-30	2015-05-07	Novartis Ag	Inhibiteurs du facteur b du complément à base de 2-benzyl-benzimidazole et leurs utilisations
WO2015118598A1 (fr) *	2014-02-06	2015-08-13	株式会社Ｊｏｌｅｄ	Dispositif d'affichage
JP2017206437A (ja) *	2014-08-18	2017-11-24	エーザイ・アール・アンド・ディー・マネジメント株式会社	４−アミノピリジン誘導体
JP6444525B2 (ja) *	2015-02-27	2018-12-26	ナントバイオ，インコーポレイテッド	キナーゼ阻害剤としてのピリミジン誘導体及びその治療用途
EP3317258A4 (fr) *	2015-07-01	2019-06-26	Pharmakea, Inc.	Inhibiteurs de lysyl oxydase-like 2 et utilisations desdits inhibiteurs
BR112018000808A2 (pt)	2015-07-16	2018-09-04	Array Biopharma Inc	compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
TN2018000138A1 (en)	2015-10-26	2019-10-04	Array Biopharma Inc	Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN108137555B (zh)	2015-11-06	2021-02-19	豪夫迈·罗氏有限公司	可用于治疗cns疾病的二氢吲哚-2-酮衍生物
EP3371174B1 (fr)	2015-11-06	2021-03-17	H. Hoffnabb-La Roche Ag	Dérivés d'indolin-2-one
SG11201803796SA (en)	2015-11-06	2018-06-28	Hoffmann La Roche	Indolin-2-one derivatives
WO2017076931A1 (fr)	2015-11-06	2017-05-11	F. Hoffmann-La Roche Ag	Dérivés indolin-2-one destinés à être utilisés dans le traitement du snc et de troubles apparentés
US10045991B2 (en)	2016-04-04	2018-08-14	Loxo Oncology, Inc.	Methods of treating pediatric cancers
PH12018502124B1 (en)	2016-04-04	2024-04-12	Loxo Oncology Inc	Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
RS65988B1 (sr)	2016-04-04	2024-10-31	Loxo Oncology Inc	Postupak lečenja pedijatrijskih karcinoma
ES2952056T3 (es)	2016-05-18	2023-10-26	Loxo Oncology Inc	Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
AU2017342240A1 (en)	2016-10-14	2019-04-04	Novartis Ag	Methods for treating ocular disease using inhibitors of CSF-1R
JOP20190092A1 (ar)	2016-10-26	2019-04-25	Array Biopharma Inc	عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (fr)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Inhibiteurs de ret
WO2018136661A1 (fr)	2017-01-18	2018-07-26	Andrews Steven W	Composés de pyrazolo[1,5-a]pyrazine substitués utilisés en tant qu'inhibiteurs de la kinase ret
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
JOP20190245A1 (ar)	2017-04-20	2019-10-15	Novartis Ag	أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
TWI876442B (zh)	2017-10-10	2025-03-11	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087972C (fr)	2018-01-18	2023-01-10	Array Biopharma Inc.	Composes de pyrazolyl[4,3-c]pyridine substitues utilises en tant qu'inhibiteurs de la kinase ret
CN111971286B (zh)	2018-01-18	2023-04-14	阿雷生物药品公司	作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
TW201938169A (zh)	2018-01-18	2019-10-01	美商亞雷生物製藥股份有限公司	作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN108586454B (zh) *	2018-02-13	2021-02-26	沈阳药科大学	四氢吡啶并[4,3-d]嘧啶类衍生物及其用途
CN110386892B (zh) *	2018-04-16	2020-08-18	新发药业有限公司	一种4-氟-5-羟基-2-甲基-1h-吲哚的制备方法
CN110483482A (zh)	2018-05-15	2019-11-22	北京诺诚健华医药科技有限公司	吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
KR102653681B1 (ko)	2018-07-31	2024-04-03	록쏘 온콜로지, 인코포레이티드	(s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
US11964988B2 (en)	2018-09-10	2024-04-23	Array Biopharma Inc.	Fused heterocyclic compounds as RET kinase inhibitors
JP2022515198A (ja)	2018-12-19	2022-02-17	アレイバイオファーマインコーポレイテッド	ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
WO2020131674A1 (fr)	2018-12-19	2020-06-25	Array Biopharma Inc.	Dérivés de 7-((3,5-diméthoxyphényl)amino)quinoxaline servant d'inhibiteurs de fgfr pour le traitement du cancer
US20220213064A1 (en) *	2019-04-12	2022-07-07	National Health Research Institutes	Heterocyclic compounds as kinase inhibitors for therapeutic uses
IL294214B1 (en)	2019-12-27	2025-12-01	Schr?Dinger Inc	Cyclic compounds and methods of using same
CN113666911B (zh) *	2020-08-11	2025-08-26	河南迈英诺医药科技有限公司	Fgfr抑制剂化合物及其用途
CN116490507A (zh)	2020-09-10	2023-07-25	薛定谔公司	用于治疗癌症的杂环包缩合cdc7激酶抑制剂
EP4284804A1 (fr)	2021-01-26	2023-12-06	Schrödinger, Inc.	Composés tricycliques utiles dans le traitement du cancer, des troubles auto-immuns et des troubles inflammatoires
TW202300150A (zh)	2021-03-18	2023-01-01	美商薛定諤公司	環狀化合物及其使用方法
KR20240138095A (ko)	2022-01-24	2024-09-20	노파르티스 아게	보체 인자 b 억제제로서의 스피로사이클릭 피페리디닐 유도체 및 이의 용도
JP2025511100A (ja)	2022-04-01	2025-04-15	ノバルティスアーゲー	補体因子ｂ阻害剤及びその使用
WO2025059027A1 (fr)	2023-09-11	2025-03-20	Schrödinger, Inc.	Dérivés de cyclopenta[e]pyrazolo[1,5-a]pyrimidine utilisés en tant qu'inhibiteurs de malt1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2241781T3 (es)	2000-02-09	2005-11-01	Novartis Ag	Derivados de piridina inhibidores de la angiogenesis y/o del receptor tirosina quinasa de vegf.
JP3712393B2 (ja) *	2000-10-20	2005-11-02	エーザイ株式会社	含窒素芳香環誘導体
GB0126902D0 (en)	2001-11-08	2002-01-02	Novartis Ag	Organic compounds
AR037647A1 (es) *	2002-05-29	2004-12-01	Novartis Ag	Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
MXPA05001536A (es)	2002-08-30	2005-04-19	Eisai Co Ltd	Derivados aromaticos que contienen nitrogeno.
TW200418466A (en)	2002-11-06	2004-10-01	Smithkline Beecham Corp	Chemical compounds
SE0302324D0 (sv)	2003-08-28	2003-08-28	Astrazeneca Ab	Novel compounds
GB0420520D0 (en) *	2004-09-15	2004-10-20	Novartis Ag	Organic compounds
PE20060664A1 (es) *	2004-09-15	2006-08-04	Novartis Ag	Amidas biciclicas como inhibidores de cinasa
GB0421525D0 (en) *	2004-09-28	2004-10-27	Novartis Ag	Inhibitors of protein kineses
DOP2006000051A (es)	2005-02-24	2006-08-31	Lilly Co Eli	Inhibidores de vegf-r2 y métodos
GT200600411A (es) *	2005-09-13	2007-05-21	Novartis Ag	Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
JP2009532440A (ja)	2006-04-07	2009-09-10	ノバルティスアクチエンゲゼルシャフト	ａ）ピリミジルアミノベンズアミド化合物、およびｂ）Ｔｈｒ３１５Ｉｌｅキナーゼ阻害剤を含む、組合せ剤
JP2010535773A (ja)	2007-08-10	2010-11-25	グラクソスミスクラインエルエルシー	ウイルス感染を治療するための窒素含有二環式化学物質
WO2009036066A1 (fr)	2007-09-10	2009-03-19	Curis, Inc.	Inhibiteurs du récepteur du facteur de croissance endothélial vasculaire (vegfr) contenant une fraction de liaison au zinc
TWI440638B (zh)	2007-10-30	2014-06-11	Otsuka Pharma Co Ltd	雜環化合物及其藥學組成物

2009
- 2009-12-06 JO JOP/2009/0466A patent/JO3265B1/ar active
- 2009-12-07 EA EA201100873A patent/EA019681B1/ru not_active IP Right Cessation
- 2009-12-07 DK DK09774876.8T patent/DK2376478T3/en active
- 2009-12-07 KR KR1020117015822A patent/KR101345956B1/ko not_active Expired - Fee Related
- 2009-12-07 UY UY0001032302A patent/UY32302A/es not_active Application Discontinuation
- 2009-12-07 PE PE2011001180A patent/PE20110835A1/es not_active Application Discontinuation
- 2009-12-07 LT LTEP09774876.8T patent/LT2376478T/lt unknown
- 2009-12-07 MX MX2011006093A patent/MX2011006093A/es active IP Right Grant
- 2009-12-07 ES ES09774876.8T patent/ES2633959T3/es active Active
- 2009-12-07 PL PL09774876T patent/PL2376478T3/pl unknown
- 2009-12-07 HR HRP20171075TT patent/HRP20171075T1/hr unknown
- 2009-12-07 HU HUE09774876A patent/HUE035292T2/en unknown
- 2009-12-07 SI SI200931684A patent/SI2376478T1/sl unknown
- 2009-12-07 AU AU2009326110A patent/AU2009326110B9/en not_active Ceased
- 2009-12-07 PT PT97748768T patent/PT2376478T/pt unknown
- 2009-12-07 CN CN201310101393.0A patent/CN103193773B/zh active Active
- 2009-12-07 MY MYPI2011002414A patent/MY155649A/en unknown
- 2009-12-07 US US12/632,396 patent/US8242125B2/en active Active
- 2009-12-07 NZ NZ593030A patent/NZ593030A/xx not_active IP Right Cessation
- 2009-12-07 JP JP2011540046A patent/JP5580330B2/ja active Active
- 2009-12-07 CA CA2745922A patent/CA2745922C/fr not_active Expired - Fee Related
- 2009-12-07 CN CN200980156323.7A patent/CN102307870B/zh active Active
- 2009-12-07 RS RS20170576A patent/RS56076B1/sr unknown
- 2009-12-07 WO PCT/EP2009/066540 patent/WO2010066684A2/fr not_active Ceased
- 2009-12-07 SG SG2011036878A patent/SG171784A1/en unknown
- 2009-12-07 EP EP09774876.8A patent/EP2376478B1/fr active Active
- 2009-12-07 NZ NZ601656A patent/NZ601656A/xx not_active IP Right Cessation
- 2009-12-07 BR BRPI0922552A patent/BRPI0922552A2/pt not_active IP Right Cessation
- 2009-12-07 AR ARP090104731A patent/AR074499A1/es unknown
- 2009-12-07 CU CU2011000129A patent/CU24097B1/es active IP Right Grant
- 2009-12-08 TW TW098141904A patent/TWI429640B/zh not_active IP Right Cessation
2011
- 2011-05-23 CR CR20110270A patent/CR20110270A/es unknown
- 2011-05-23 ZA ZA2011/03759A patent/ZA201103759B/en unknown
- 2011-05-23 TN TN2011000263A patent/TN2011000263A1/fr unknown
- 2011-05-23 IL IL213068A patent/IL213068A/en not_active IP Right Cessation
- 2011-06-07 EC EC2011011113A patent/ECSP11011113A/es unknown
- 2011-06-08 CL CL2011001378A patent/CL2011001378A1/es unknown
- 2011-06-09 HN HN2011001593A patent/HN2011001593A/es unknown
- 2011-06-09 SV SV2011003939A patent/SV2011003939A/es unknown
- 2011-06-10 CO CO11072268A patent/CO6382119A2/es active IP Right Grant
2012
- 2012-06-05 US US13/488,760 patent/US8431584B2/en active Active
- 2012-09-13 US US13/613,019 patent/US8492393B2/en active Active
- 2012-09-13 US US13/613,034 patent/US8486954B2/en active Active
- 2012-09-13 US US13/613,062 patent/US8501756B2/en active Active
- 2012-09-13 US US13/613,053 patent/US8541432B2/en active Active
2017
- 2017-07-19 CY CY20171100772T patent/CY1119091T1/el unknown

Also Published As

Publication number	Publication date
CA2745922C (fr)	2017-06-27
NZ601656A (en)	2013-11-29
JP2012511535A (ja)	2012-05-24
AU2009326110A1 (en)	2011-06-23
TW201026686A (en)	2010-07-16
JP5580330B2 (ja)	2014-08-27
CR20110270A (es)	2011-06-28
US8242125B2 (en)	2012-08-14
US20130005750A1 (en)	2013-01-03
LT2376478T (lt)	2017-07-10
WO2010066684A2 (fr)	2010-06-17
US8431584B2 (en)	2013-04-30
AU2009326110B2 (en)	2013-09-12
CN103193773B (zh)	2014-12-10
US8486954B2 (en)	2013-07-16
EA201100873A1 (ru)	2011-12-30
CU20110129A7 (es)	2012-01-31
CN103193773A (zh)	2013-07-10
SV2011003939A (es)	2011-07-28
HUE035292T2 (en)	2018-05-02
NZ593030A (en)	2013-11-29
CU24097B1 (es)	2015-06-30
US20130005753A1 (en)	2013-01-03
KR101345956B1 (ko)	2014-02-06
US20120245187A1 (en)	2012-09-27
IL213068A (en)	2017-02-28
RS56076B1 (sr)	2017-10-31
TWI429640B (zh)	2014-03-11
CY1119091T1 (el)	2018-01-10
MY155649A (en)	2015-11-13
US20100168082A1 (en)	2010-07-01
ECSP11011113A (es)	2011-07-29
SG171784A1 (en)	2011-07-28
CN102307870A (zh)	2012-01-04
HRP20171075T1 (hr)	2017-10-06
CL2011001378A1 (es)	2011-11-25
AU2009326110B9 (en)	2013-10-31
IL213068A0 (en)	2011-07-31
AR074499A1 (es)	2011-01-19
ES2633959T3 (es)	2017-09-26
PE20110835A1 (es)	2011-11-25
DK2376478T3 (en)	2017-07-31
EA019681B1 (ru)	2014-05-30
MX2011006093A (es)	2011-06-21
HN2011001593A (es)	2014-01-20
EP2376478A2 (fr)	2011-10-19
PT2376478T (pt)	2017-06-30
PL2376478T3 (pl)	2017-10-31
ZA201103759B (en)	2012-01-25
SI2376478T1 (sl)	2017-07-31
EP2376478B1 (fr)	2017-04-19
US20130012529A1 (en)	2013-01-10
WO2010066684A3 (fr)	2010-10-14
CA2745922A1 (fr)	2010-06-17
BRPI0922552A2 (pt)	2021-11-03
CN102307870B (zh)	2014-06-18
JO3265B1 (ar)	2018-09-16
US8541432B2 (en)	2013-09-24
US8492393B2 (en)	2013-07-23
US8501756B2 (en)	2013-08-06
UY32302A (es)	2010-07-30
KR20110098799A (ko)	2011-09-01
CO6382119A2 (es)	2012-02-15
US20130005751A1 (en)	2013-01-03

Publication	Publication Date	Title
JO3265B1 (ar)	2018-09-16	مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
TW200626576A (en)	2006-08-01	Bicyclic amides as kinase inhibitors
AU2011338389A8 (en)	2013-07-18	Bicyclic compounds as Pim inhibitors
MX2010014233A (es)	2011-03-25	Compuestos quimicos 251.
IN2012DN01453A (fr)	2015-06-05
EA201290078A1 (ru)	2012-11-30	Гетероциклические соединения для ингибирования pask
EA201000552A1 (ru)	2010-12-30	Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
EA200901133A1 (ru)	2010-04-30	Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
WO2011127333A3 (fr)	2012-02-02	Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
MX2012001838A (es)	2012-02-29	Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MX2009012066A (es)	2009-11-19	Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
EA200971107A1 (ru)	2010-06-30	Катехоламиновые производные, полезные для лечения болезни паркинсона
JO3007B1 (ar)	2016-09-05	مركبات و تركيبات كمثبطات كيناز بروتين
UA104489C2 (uk)	2014-02-10	Сполуки для лікування дисліпідемії та споріднених хвороб
MX2009005622A (es)	2009-06-12	Dihidro-imidazoles sustituidos y su uso en el tratamiento de tumores.
MX2009006327A (es)	2009-06-23	Compuestos heterociclicos y metodos de uso de los mismos.
MX2014003194A (es)	2015-03-19	3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
TW200745043A (en)	2007-12-16	Substituted pyrazoline compounds, their preparation and use as medicaments
MX2009010374A (es)	2010-03-04	Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
IN2012DN00953A (fr)	2015-04-10
MX2009013482A (es)	2010-01-27	Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.
TW200745042A (en)	2007-12-16	Substituted pyrazoline compounds, their preparation and use as medicaments
MX2008013477A (es)	2008-10-29	Compuestos biciclicos de tetrahidropirrol.
WO2006138589A3 (fr)	2009-04-16	Ligands de recepteur opioide
UA100390C2 (en)	2012-12-25	Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors